	JUL 1 6 2002 W		
	Filing Date 9/913,521 August 13, 2001	Examiner Angell, J.	Group Art Unit
	SHORTENED-CHAIN POLYNUCLEOTIDE AND		ON THEREOF
	SHORTENED-CHAIN TODINGCEDG TIDE III.	COPY OF PAPER ORIGINALLY FILI	RS DECEIVE
	Add	ress to:	JUL D
	Assistant Commi	issioner for Patents n, D.C. 20231	TECH CENTER 160
	37 CFF	R 1.97(b)	
	The Information Disclosure Statement submitted h of a national application; within three months of the CFR 1.491 in an international application; or bef merits, whichever event occurs last.	e date of entry of the national s	stage as set forth in 37
	mone, who is the control of the cont		
		R 1.97(c)	
2. 🛚		nerewith is being filed after throne national stage as set forth i	n 37 CFR 1.491 in an
2. 🛚	37 CFF The Information Disclosure Statement submitted to of a national application, or the date of entry of the international application; or after the mailing data.	nerewith is being filed after throne national stage as set forth ine of a first Office Action on	n 37 CFR 1.491 in an
2. 🛚	The Information Disclosure Statement submitted to fa national application, or the date of entry of the international application; or after the mailing date occurred last but before the mailing date of either:	nerewith is being filed after throne national stage as set forth ine of a first Office Action on 3, or	n 37 CFR 1.491 in an
2. 🛚	The Information Disclosure Statement submitted to fa national application, or the date of entry of trinternational application; or after the mailing dat occurred last but before the mailing date of either: 1. a Final Action under 37 CFR 1.113	nerewith is being filed after throne national stage as set forth ine of a first Office Action on 3, or	n 37 CFR 1.491 in an
2. 🛚	The Information Disclosure Statement submitted to of a national application, or the date of entry of the international application; or after the mailing date occurred last but before the mailing date of either: 1. a Final Action under 37 CFR 1.113 2. a Notice of Allowance under 37 CFR	nerewith is being filed after throne national stage as set forth ine of a first Office Action on 3, or	n 37 CFR 1.491 in an
2. 🛚	The Information Disclosure Statement submitted to fanational application, or the date of entry of the international application; or after the mailing date occurred last but before the mailing date of either: 1. a Final Action under 37 CFR 1.113 2. a Notice of Allowance under 37 CFR whichever occurs first.	nerewith is being filed after throne national stage as set forth inee of a first Office Action on a stage as set forth inee of a first Office Action on a stage of the stage o	n 37 CFR 1.491 in an
2. 🛚	The Information Disclosure Statement submitted to fa national application, or the date of entry of the international application; or after the mailing date occurred last but before the mailing date of either: 1. a Final Action under 37 CFR 1.113 2. a Notice of Allowance under 37 CFR whichever occurs first. Also submitted herewith is:	nerewith is being filed after throne national stage as set forth inee of a first Office Action on a stage as set forth inee of a first Office Action on a stage of the stage o	n 37 CFR 1.491 in an
2. 🛚	The Information Disclosure Statement submitted to fanational application, or the date of entry of the international application; or after the mailing date occurred last but before the mailing date of either: 1. a Final Action under 37 CFR 1.113 2. a Notice of Allowance under 37 CFR whichever occurs first. Also submitted herewith is: a certification as specified in 37 CFR 1.97(e)	nerewith is being filed after throne national stage as set forth inee of a first Office Action on an analysis.	n 37 CFR 1.491 in an the merits, whichever
2. 🛚	The Information Disclosure Statement submitted to fanational application, or the date of entry of the international application; or after the mailing date occurred last but before the mailing date of either: 1. a Final Action under 37 CFR 1.113 2. a Notice of Allowance under 37 CFR whichever occurs first. Also submitted herewith is: a certification as specified in 37 CFR 1.97(error occurs first).	nerewith is being filed after throne national stage as set forth inee of a first Office Action on an analysis.	n 37 CFR 1.491 in an the merits, whichever

RANSMITTAL OF INFORM TION DISCLOS (Under 37 CFR 1.97(b) or 1.97(SURE STATEMEN (c))	Docket No. 44342.014000
Re Application Of: MATSUTAMA, et al.		
Serial No. Filing Date August 13, 2001	Examiner Angell, J.	Group Art Unit 1635
tle: SHORTENED-CHAIN POLYNUCLEOTIDE AND	METHOD FOR PREPARATIO	N THEREOF
He. SHORPEROD CONTRACT	COPY OF PAPEF ORIGINALLY FILE	RECEIVED
Paym (Only complete if Applicant elects	ent of Fee to pay the fee set forth in 37 CFR 1.17	TECH CENTER 160
as described below. A duplicate copy of this shee Charge the amount of \$180.00 Credit any overpayment. Charge any additional fee required. Certificate of Transmission by Facsimile* I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No.) on (Date) Signature *This certificate may only be used if paying by deposit account. Signature Eugene C. Rzucidlo, Esq. Reg. No.: 31,900 Greenberg Traurig, LLP 885 Third Avenue, 21st Floor New York, NY 10022 212-801-2100	Certificate of Mailing I certify that this document and 07/10/2002 with	and fee is being deposited the U.S. Postal Service as . 1.8 and is addressed to the Patents, Washington, D.C. Our Milling Correspondence rramone